Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

A rapid, high-sensitivity SARS-CoV-2 nucleocapsid immunoassay to aid diagnosis of acute COVID-19 at the point of care

Paul K. Drain, Madhavi Ampajwala, Christopher Chappel, Andre B. Gvozden, Melanie Hoppers, Melody Wang, Robert Rosen, Stephen Young, Edward Zissman, Michalina Montano
doi: https://doi.org/10.1101/2020.12.11.20238410
Paul K. Drain
1Department of Global Health, University of Washington, Seattle, WA, USA
2Department of Medicine, University of Washington, Seattle, WA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: pkdrain@uw.edu
Madhavi Ampajwala
3Village Health Partners, Plano, TX, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christopher Chappel
4Chappel Group, Kissimmee, FL, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andre B. Gvozden
5Gvozden Pediatrics, Millersville, MD, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Melanie Hoppers
6Clinical Research Solutions, Jackson, TN, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Melody Wang
1Department of Global Health, University of Washington, Seattle, WA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert Rosen
7Ardmore Family Practice, Winston-Salem, NC, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stephen Young
8Tricore Reference Laboratories, Albuquerque, NM, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Edward Zissman
9Children’s Research, LLC, Altamonte Springs, FL, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michalina Montano
1Department of Global Health, University of Washington, Seattle, WA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Background The LumiraDx SARS-CoV-2 antigen test, which uses a high-sensitivity, microfluidic immunoassay to detect the nucleocapsid protein of SARS-CoV-2, was evaluated for diagnosing acute COVID-19 in adults and children across point-of-care settings.

Methods Two paired anterior nasal swabs or two paired nasopharyngeal swabs were collected from each participant. Swabs were tested by the LumiraDx SARS-CoV-2 antigen test and compared with real-time PCR (rt-PCR; Roche cobas 6800 platform). Positive- and negative predictive values and likelihood ratios were calculated. Results stratified based on gender, age, duration of symptoms, and rt-PCR cycle threshold.

Results Out of the 512 participants, aged 0-90 years, of this prospective validation study, 414 (81%) were symptomatic for COVID-19 and 123 (24%) swabs were positive for SARS-CoV-2 based on rt-PCR testing. Compared with rt-PCR, the 12-minute swab test had 97.6% sensitivity and 96.6% specificity within 12 days of symptom onset, representing the period of infectivity. All (100%) samples detected within 33 rt-PCR cycles were also identified using the antigen test. Results were consistent across age and gender. Despite being performed by minimally trained healthcare workers, the user error rate of the test system was 1%.

Conclusion The rapid high-sensitivity assay using nasopharyngeal or anterior nasal sampling may offer significant improvements for diagnosing acute SARS-CoV-2 infection in clinic- and community-based settings.

Summary A 12-minute nasal swab test detects 97.6% of COVID-19 infections, compared to gold standard real-time PCR testing, up to 12 days following symptom onset using a microfluidic immunoassay for SARS-CoV-2 nucleocapsid protein.

Competing Interest Statement

The authors have declared no competing interest.

Clinical Trial

NCT04557046

Funding Statement

Funding. The study was funded by LumiraDx Ltd.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The clinical study received ethical approval from WCG Institutional Review Board and all participants provided informed consent (NCT 04557046 clinicaltrials.gov).

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

Data and materials availability: The study dataset may be provided upon request.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted December 14, 2020.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
A rapid, high-sensitivity SARS-CoV-2 nucleocapsid immunoassay to aid diagnosis of acute COVID-19 at the point of care
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
A rapid, high-sensitivity SARS-CoV-2 nucleocapsid immunoassay to aid diagnosis of acute COVID-19 at the point of care
Paul K. Drain, Madhavi Ampajwala, Christopher Chappel, Andre B. Gvozden, Melanie Hoppers, Melody Wang, Robert Rosen, Stephen Young, Edward Zissman, Michalina Montano
medRxiv 2020.12.11.20238410; doi: https://doi.org/10.1101/2020.12.11.20238410
Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Citation Tools
A rapid, high-sensitivity SARS-CoV-2 nucleocapsid immunoassay to aid diagnosis of acute COVID-19 at the point of care
Paul K. Drain, Madhavi Ampajwala, Christopher Chappel, Andre B. Gvozden, Melanie Hoppers, Melody Wang, Robert Rosen, Stephen Young, Edward Zissman, Michalina Montano
medRxiv 2020.12.11.20238410; doi: https://doi.org/10.1101/2020.12.11.20238410

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (62)
  • Allergy and Immunology (142)
  • Anesthesia (46)
  • Cardiovascular Medicine (415)
  • Dentistry and Oral Medicine (70)
  • Dermatology (48)
  • Emergency Medicine (144)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (171)
  • Epidemiology (4861)
  • Forensic Medicine (3)
  • Gastroenterology (183)
  • Genetic and Genomic Medicine (676)
  • Geriatric Medicine (70)
  • Health Economics (192)
  • Health Informatics (630)
  • Health Policy (321)
  • Health Systems and Quality Improvement (206)
  • Hematology (85)
  • HIV/AIDS (156)
  • Infectious Diseases (except HIV/AIDS) (5343)
  • Intensive Care and Critical Care Medicine (331)
  • Medical Education (93)
  • Medical Ethics (24)
  • Nephrology (75)
  • Neurology (686)
  • Nursing (42)
  • Nutrition (115)
  • Obstetrics and Gynecology (126)
  • Occupational and Environmental Health (208)
  • Oncology (440)
  • Ophthalmology (140)
  • Orthopedics (36)
  • Otolaryngology (90)
  • Pain Medicine (35)
  • Palliative Medicine (16)
  • Pathology (129)
  • Pediatrics (194)
  • Pharmacology and Therapeutics (131)
  • Primary Care Research (84)
  • Psychiatry and Clinical Psychology (781)
  • Public and Global Health (1817)
  • Radiology and Imaging (325)
  • Rehabilitation Medicine and Physical Therapy (138)
  • Respiratory Medicine (255)
  • Rheumatology (86)
  • Sexual and Reproductive Health (69)
  • Sports Medicine (62)
  • Surgery (100)
  • Toxicology (23)
  • Transplantation (29)
  • Urology (37)